ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,313.67
1.22%
Dow Jones
38,884.26
0.08%
Gold vs US Dollar
2,314.12
-0.50%
Brent Oil
82.865
-0.73%
Bitcoin
63,036.30
-0.21%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Genfit (GNFT)

  7. Genfit (GNFT) News

Genfit (GNFT)

Genfit
Date:
Sort by:
 Showing the most relevant articles for your search:EU:GNFT
DateTimeSourceHeadlineSymbolCompany
25/04/202421:10GlobeNewswire Inc.GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)EU:GNFTGenfit
25/04/202421:10GlobeNewswire Inc.GENFIT : Publication du rapport de performance extra-financière 2024 (exercice 2023)EU:GNFTGenfit
25/04/202421:10GlobeNewswire Inc.GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)EU:GNFTGenfit
15/04/202421:10GlobeNewswire Inc.GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory DocumentsEU:GNFTGenfit
15/04/202421:10GlobeNewswire Inc.GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory DocumentsEU:GNFTGenfit
15/04/202421:10GlobeNewswire Inc.GENFIT : Assemblée Générale Mixte du 22 mai 2024 — modalités de mise à disposition des documents préparatoires EU:GNFTGenfit
05/04/202419:00GlobeNewswire Inc.GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-FEU:GNFTGenfit
05/04/202419:00GlobeNewswire Inc.GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-FEU:GNFTGenfit
05/04/202419:00GlobeNewswire Inc.GENFIT : Mise à disposition du Document d’Enregistrement Universel 2023 et du Rapport Annuel Form 20-F 2023EU:GNFTGenfit
04/04/202421:10GlobeNewswire Inc.GENFIT : Résultats financiers annuels 2023 et point sur les activités de la SociétéEU:GNFTGenfit
04/04/202421:10GlobeNewswire Inc.GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate UpdateEU:GNFTGenfit
04/04/202421:10GlobeNewswire Inc.GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate UpdateEU:GNFTGenfit
29/02/202421:10GlobeNewswire Inc.GENFIT annonce son chiffre d’affaires et sa position de trésorerie au 31 décembre 2023EU:GNFTGenfit
29/02/202421:10GlobeNewswire Inc.GENFIT Announces Revenues and Cash Position as of December 31, 2023EU:GNFTGenfit
29/02/202421:10GlobeNewswire Inc.GENFIT Announces Revenues and Cash Position as of December 31, 2023EU:GNFTGenfit
15/01/202421:10GlobeNewswire Inc.GENFIT Announces 2024 Financial Calendar  EU:GNFTGenfit
15/01/202421:10GlobeNewswire Inc.GENFIT annonce son calendrier financier pour 2024EU:GNFTGenfit
15/01/202421:10GlobeNewswire Inc.GENFIT Announces 2024 Financial Calendar  EU:GNFTGenfit
11/01/202421:10GlobeNewswire Inc.GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et CommercialEU:GNFTGenfit
11/01/202421:10GlobeNewswire Inc.GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et CommercialEU:GNFTGenfit
08/12/202306:55GlobeNewswire Inc.GENFIT : Perspectives 2024 actualisées suite à la validation des dépôts de demandes d’autorisation d’élafibranor dans la Cholangite Biliaire Primitive (PBC)EU:GNFTGenfit
08/12/202306:55GlobeNewswire Inc.GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)EU:GNFTGenfit
08/12/202306:55GlobeNewswire Inc.GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)EU:GNFTGenfit
07/12/202310:15GlobeNewswire Inc.Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBCEU:GNFTGenfit
07/12/202310:15GlobeNewswire Inc.Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBCEU:GNFTGenfit
07/12/202310:15GlobeNewswire Inc.Ipsen confirme la décision de la FDA d'accorder un examen prioritaire pour le dépôt du dossier de demande d'autorisation d'elafibranor dans le traitement de la cholangite biliaire primitive, une maladie cholestatique rare du foieEU:GNFTGenfit
06/12/202316:30GlobeNewswire Inc.GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical TrialsEU:GNFTGenfit
06/12/202316:30GlobeNewswire Inc.GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical TrialsEU:GNFTGenfit
06/12/202316:30GlobeNewswire Inc.GENFIT annonce une publication dans le Journal of Hepatology sur la performance et la précision de NIS2+™ en tant qu’outil de screening pour le recrutement des patients dans les essais cliniques MASHEU:GNFTGenfit
16/11/202321:10GlobeNewswire Inc.GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023EU:GNFTGenfit
 Showing the most relevant articles for your search:EU:GNFT

Your Recent History

LSE
AGL
Angle
LSE
AAZ
Anglo Asian Mining
LSE
CHLL
Chill Brands
LSE
EZJ
Easyjet
LSE
TERN
Tern
LSE
MIN
Minoan
LSE
FDEV
Frontier Developments
LSE
PANR
Pantheon Resources
LSE
KEFI
Kefi Gold And Copper
LSE
BIRD
Blackbird
LSE
BOO
Boohoo
LSE
PXC
Phoenix Copper
LSE
SYME
Supply@me Capital
LSE
POS
Plexus
LSE
SCE
Surface Transforms
LSE
ALGW
Alpha Growth
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved